Why Geron Stock Is Down Today

Geron Corporation (NASDAQ: GERN) is down 22% at $0.90 by late morning after announcing it would stop its trial of Imetelstat in myelofibrosis. That removes a late-stage test of the drug as a possible treatment for this blood cancer.

What Geron Corporation Does

Geron sells Imetelstat as Rytelo and studies the drug in blood disorders. Rytelo is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes, a different blood disorder.

Geron Imetelstat Myelofibrosis Trial Results

The study was in Phase 3, the final trial stage before a drug approval decision. It tested patients whose cancer returned or did not respond after earlier treatment. Independent trial reviewers recommended stopping because the study was unlikely to meet its main goal: helping patients live longer.

Geron Imetelstat Safety Findings

Geron reported no new safety findings that changed the drug’s known risks or required extra monitoring. The setback concerns the expected treatment benefit, rather than a newly identified safety issue.

Geron Trading Volume Today

Trading reached about 48 million shares as investors reacted to the lost development opportunity. The decline was the biggest daily move in the last year, showing how sharply expectations changed.

Quick Financial Overview

Loss-making Geron held $300.8M in cash, cash equivalents, and short-term investments as of June 30, 2026, including cash and assets readily turned into cash. That covers about fifty-seven months at its latest quarterly spending rate. It is a small-cap, with a modest total stock value of $578.7M.

Geron Cash Use Of $15.8M

The latest quarter used $15.8M in operating cash, the money spent running the business. That spending rate provides a funding estimate, not a promise that future costs will stay unchanged.

Geron Revenue And Earnings

The latest reported quarter generated $57.5M in revenue and a net loss of $16.7M. Geron has an existing sales business to support, alongside its research costs.

Geron Shares Available To Trade

Geron has about 535 million shares available for public trading. The selloff therefore occurred in a stock with a broad supply of tradable shares.

Geron Stock Is down 40% Over Six Months

Geron traded around $1.50 six months ago. Today’s decline extends that longer slide rather than reversing a recent sustained rally.

Geron Earnings Date And Business Update

Geron will release its third-quarter results before the market opens on November 4, 2026. The business update offers the next dated check on demand for its approved drug.

Conclusion

Stronger Rytelo sales would support the remaining growth case, while weaker sales would leave less business progress to offset the research setback. Geron plans a detailed trial analysis without a release date, but has announced no next myelofibrosis trial or regulatory step. Its cash position covers the wait for that work.

Start Your Trial Now!